Expanding Liver Transplant Immunosuppression Minimization Via Everolimus (ELIMINATE)
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus (CTOT-43)
This is a study to determine the safety, efficacy, and tolerability of taking away the anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with everolimus monotherapy to preserve renal function. Two hundred - seventy (270) subjects will be randomized 2:1 into one of two groups between 2-3 months post-transplant. Seventy participants will be placed into an observational group and will remain on their current post-transplant medications. The duration of the study from time of enrollment is 18-20 months.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This study is a multicenter 2:1 randomized nonblinded phase II interventional clinical trial in liver transplant recipients. The primary objective is to determine the safety, efficacy, and tolerability of tacrolimus minimization and eventual withdrawal in conjunction with everolimus monotherapy to preserve renal function. Study subjects will undergo first reduction of tacrolimus with the addition of everolimus. If everolimus is tolerated, subjects will be randomized 2:1 into one of two interventional arms. The first interventional arm will undergo a stepwise reduction of tacrolimus and be on everolimus monotherapy for the remainder of the study. The second interventional arm will remain on the initial reduced tacrolimus dose and everolimus. If subjects prior to randomization are unable to tolerate everolimus, these subjects will be placed in the observational group. These subjects will stop taking everolimus and resume their immunosuppression therapy prior to study enrollment.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Tracia Debnam, MS
- Phone Number: 301-761-7414
- Email: Tracia.debnam@nih.gov
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Recruiting
- Mayo Clinic Hospital Arizona (Site #: 71144)
-
Principal Investigator:
- Hugo Vargas, MD
-
-
California
-
Los Angeles, California, United States, 90095
- Not yet recruiting
- Ronald Regan at UCLA Medical Center (Site #: 71123)
-
Principal Investigator:
- Sammy Saab, MD
-
San Diego, California, United States, 92121
- Recruiting
- University of California, San Diego (Site #: 71179)
-
Principal Investigator:
- Pranab Barman, MD
-
San Francisco, California, United States, 94143
- Recruiting
- University of California, San Francisco (Site #: 71108)
-
Principal Investigator:
- Sandy Feng, MD
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University (Site #: 71110)
-
Principal Investigator:
- Justin Boike, MD
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- University of Michigan (Site #: 71154)
-
Principal Investigator:
- Sasha Shingina, MD
-
-
New York
-
New York, New York, United States, 10029
- Recruiting
- Icahn School of Medicine at Mount Sinai (Site #: 71115)
-
Principal Investigator:
- Thomas Schiano, MD
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke University Medical Center (Site #: 71139)
-
Principal Investigator:
- Matthew Kappus, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania (Site #: 71111)
-
Principal Investigator:
- Abraham Shaked, MD
-
Pittsburgh, Pennsylvania, United States, 15260
- Recruiting
- University of Pittsburgh Medical Center (Site #: 71170)
-
Principal Investigator:
- Scott Biggins, MD
-
-
Texas
-
Dallas, Texas, United States, 75246
- Recruiting
- Baylor Medical Center (Site #: 71153)
-
Principal Investigator:
- Robert Rahimi, MD
-
Houston, Texas, United States, 77030
- Not yet recruiting
- Houston Methodist (Site #: 71120)
-
Principal Investigator:
- Mark Ghobrial, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject and/or legal guardian must be able to understand and provide informed consent
- Adult (age greater than or equal to 18 years of age at time of informed consent) recipient of first liver transplant alone (de novo)
- Estimated glomerular filtration rate >=30 ml/min/1.73m^2 at enrollment using the CKD-EPI 2021 equation
- Treatment with tacrolimus therapy, with or without mycophenolic acid derivatives and/or corticosteroids
- Female subjects of childbearing potential with negative pregnancy test upon study entry
- All subjects of reproductive potential agreeing to use contraception for the duration of the study
- Previous vaccination or documented immunity to varicella, measles, hepatitis B, pneumococcus, influenza, zoster (if >=19 years old), and 2019-nCoV (COVID-19) as outlined in the DAIT Vaccination Guideline
Exclusion Criteria:
-
Inability or unwillingness of a participant to give written informed consent or comply with study protocol
-
Active unresolved systemic viral, bacterial, fungal, or parasitic infection requiring oral or intravenous anti-infective therapy
-
History of autoimmune liver disease including autoimmune hepatitis, primary sclerosing cholangitis, and/or primary biliary cirrhosis, or other contraindications to drug withdrawal
-
History of non-hepatic autoimmune disease requiring current or future systemic immunosuppressive therapy other than per study protocol
-
History post-transplant of Hepatic Artery Thrombosis or Portal Vein Thrombosis.
-
History of recurrent cirrhosis after liver transplantation.
-
Chronic use of systemic glucocorticoids, biological immunomodulatory therapy, or other immunosuppressive agents other than per study protocol
-
History of hepatitis B or C virus infection with detectable viral PCR at enrollment
-
History of prior organ transplantation (liver or other type)
-
History of >= 2 biopsy-proven acute cellular rejection episodes of any severity, >=1 moderate to severe rejection episode (histologically defined or requiring lymphodepletion therapy), or >= 1 antibody- mediated rejection episode
-
Active treatment with any mTOR-inhibitor agent (everolimus, sirolimus)
-
Contraindication to treatment with everolimus (open wound or wound infection; urine protein: creatinine ratio > 0.5 mg/mg; significant pancytopenia (any of the following: WBC <1.5 K/uL or ANC <1000 cells/uL or actively being treated with GCSF; Hb <8.0; platelet count <50K); serum triglycerides > 1000 mg/dL; other per PI)
-
Abnormal liver function tests on study entry: Total Bilirubin (TB)>1.5 mg/dL and Direct Bilirubin (DB) >1.0 mg/dL, Alkaline Phosphatase (AP) >200 U/L, and Alanine Aminotransaminase (ALT)>60 U/L
-
Pregnant on enrollment or plan to become pregnant during the study period
-
Participation in another clinical trial that would interfere with this study's procedures and intervention:
- Use of investigational biologic or drug (within 8 weeks of study enrollment)
- Additional blood collection that would exceed research blood draw limits
- Any other procedure or intervention, in the investigator's opinion would interfere with this study
-
Received live attenuated vaccine(s) within 2 months of enrollment
-
Current, diagnosed, mental illness or current, diagnosed, or self-reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study
-
Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Interventional Group 1
Participants in this group will slowly reduce their dose of tacrolimus and continue everolimus as their only immunosuppression medication. |
Other Names:
Other Names:
Other Names:
|
|
Experimental: Interventional Group 2
Participants in this group will continue to take reduced Tacrolimus and Everolimus IS regimen. |
Other Names:
Other Names:
- Participants randomized in this cohort maintain initial reduced dose of Tacrolimus and everolimus for study duration.
Other Names:
|
|
No Intervention: Observational Group
Participants in this group could not tolerate the addition of everolimus. These participants will not be randomized.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent change in estimated glomerular filtration rate (eGFR) by CKD-EPI 2021 equation. Between Cohorts INT-1 and INT-2
Time Frame: From Visit 2 to Visit 9 (12 months post-liver transplant)
|
From Visit 2 to Visit 9 (12 months post-liver transplant)
|
|
Proportion of subjects with treated Biopsy Proven Acute Rejection (tBPAR) per local pathology. Between cohorts INT-1 and INT-2
Time Frame: From Visit 2 to Visit 9 (12 months post-liver transplant)
|
From Visit 2 to Visit 9 (12 months post-liver transplant)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes in liver graft function: Total bilirubin
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Changes in liver graft function: Direct bilirubin
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Changes in liver graft function: Alanine Aminotransaminase (ALT)
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Changes in liver graft function: Aspartate Aminotransferase (AST)
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Changes in liver graft function: Alkaline Phosphatase
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Time to graft failure in liver function defined as relisting for transplantation, re-transplantation itself or death with failed graft
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Time to all-cause mortality
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Proportion of subjects experiencing a Major Adverse Cardiac Event (MACE)
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Proportion of subjects experiencing infection requiring hospitalization
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Proportion of subjects experiencing any malignancy
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Proportion of subjects developing severe Estimated Glomerular Filtration Rate (eGFR) deterioration >40 percent from baseline using the CKD-EPI 2021 equation
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Proportion of subjects developing any major immunosuppressive therapy complications
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Proportion of subjects developing new onset peripheral edema
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Proportion of subjects developing new onset cytopenia deemed WBC <3.0x10^9 /L, Hb <8.0 g/dL, or platelets <50 x 10^9/L.
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Proportion of subjects developing new onset oral/gastrointestinal ulcerations
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Proportion of subjects developing new onset gastrointestinal symptoms (nausea, vomiting, abdominal pain, or diarrhea) related to everolimus therapy.
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Proportion of subjects developing new onset pneumonitis
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Proportion of subjects developing new onset hepatic artery thrombosis
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Proportion of subjects developing other adverse events deemed
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Proportion of subjects developing any adverse events related to everolimus therapy
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Percent change in estimated Glomerular Filtration Rate (eGFR)
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
|
Percentage of subjects with treated Biopsy Proven Acute Rejection (tBPAR)
Time Frame: From Visit 1 to Visit 11 (20 months post-liver transplant)
|
From Visit 1 to Visit 11 (20 months post-liver transplant)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Justin Boike, MD, Northwestern University Feinberg School of Medicine: Transplantation
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DAIT CTOT-43
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
IPD Sharing Time Frame
24 Months after database lock for the trial
IPD Sharing Access Criteria
Open Access
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.